1 / 8

in vivo animal testing

CAR-T cell preclinical in vivo animal testing performed in xenograft murine models derived by well-defined cell lines or primary human tumor cells. Immunodeficient mice, lacking of effective innate immunity for the absence of B cells, T cells, or NK cells, are the optimal animal models for engraftment of tumor cells and evaluation of CAR-T cells. https://www.creative-biolabs.com/car-t/car-t-preclinical-in-vivo-assay.htm

bellasmith123
Télécharger la présentation

in vivo animal testing

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CAR-T Preclinical In Vivo Assay Reference: https://www.creative-biolabs.com/car-t/car-t-preclinical-in-vivo-assay.htm

  2. Introduction • CAR-T cells are autologous or allogeneic T cells targeting specifically to antigens or markers expressed by tumor cells. In vivo assessment is of pivotal importance for investigating the factors that may affect the efficacy of CAR-T cells. The approaches of delivering CAR genes into T cells, the in vitro culture conditions, the constituents of the CAR construct, and the types of host T cells all have great impacts on CAR-T efficacy and safety. Data from in vivo assays is valuable for CAR-T optimization.

  3. What can CAR-T cells do? • CAR-T cells capable of recognizing various tumor-associated antigens (TAAs) have been tested in many clinical trials and received plenty of encouraging results. However, several potential risks such as cytokine storm have also been posed for CAR-T cell clinical application. Therefore, preclinical in vivo assessment of the efficacy and safety of CAR-T cells are essential for dosage determination and risk managements for this promising immunotherapy against cancers.

  4. How to conduct in vivo assays? • CAR-T cell preclinical in vivo animal testing performed in xenograft murine models derived by well-defined cell lines or primary human tumor cells. • Immunodeficient mice, lacking of effective innate immunity for the absence of B cells, T cells, or NK cells, are the optimal animal models for engraftment of tumor cells and evaluation of CAR-T cells. • The progression and remission of tumor cells detected in any body part throughout the whole treatment duration, obtaining an unambiguous evaluation of the therapeutic efficacy of CAR-T cells. • A series of studies to investigate several potential safety concerns of CAR-T therapy including inappropriate immune activation (cytokine level), the potential for tumorigenicity, the risks of the delivery procedure, etc. • The in vivo expansion, survival, persistence, migration, and distribution of the CAR-T cells are also systematically studied.

  5. Featured in vivo Assay Categories • Construction of Xenograft Animal Model • Strategies to Harness Cytokine Release Syndrome • Efficacy Test of CAR-T • Viability and Bio-distribution Study of CAR-T • Toxicity Evaluation of CAR-T • Quality Control for in Vivo Assays

  6. Targets for CAR-T Preclinical in vivo Assays

  7. Thanks Reference: https://www.creative-biolabs.com/car-t/car-t-preclinical-in-vivo-assay.htm

More Related